A. A. Herbert, D. Glaab, and R. Schreiber, “A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis”, J of Skin, vol. 4, no. 5, p. s35, Sep. 2020.